ABOS
Acumen Pharmaceuticals, Inc.NASDAQHealthcare$2.70+5.88%ClosedMarket Cap: $163.5M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.32
P/S
0.00
EV/EBITDA
-1.19
DCF Value
$0.38
FCF Yield
-70.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-111.3%
ROA
-98.8%
ROIC
-121.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-25.1M | $-0.42 |
| FY 2025 | $0.00 | $-121.3M | $-2.00 |
| Q3 2025 | $0.00 | $-26.5M | $-0.44 |
| Q2 2025 | $0.00 | $-41.0M | $-0.68 |
Analyst Ratings
View AllBTIGBuy
2026-03-26BTIGBuy
2026-01-27B of A SecuritiesBuy
2025-11-18B of A SecuritiesBuy
2025-08-25Trading Activity
Insider Trades
View AllRA CAPITAL MANAGEMENT, L.P.director, 10 percent owner:
SellWed Mar 18
Meisner Derek Mofficer: Chief Legal Officer & Corp Sec
SellTue Mar 10
Meisner Derek Mofficer: Chief Legal Officer & Corp Sec
SellTue Mar 10
Meisner Derek Mofficer: Chief Legal Officer & Corp Sec
SellTue Mar 03
Meisner Derek Mofficer: Chief Legal Officer & Corp Sec
SellTue Mar 03
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.34
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.